FDA Calls Novartis' Melanoma Combo Drug a Breakthrough - BioLegacy Research

FDA Calls Novartis' Melanoma Combo Drug a Breakthrough

Post author:Sam
Post published:October 22, 2017
Post category:BioPharma

The FDA based its decision on data from the COMBI-AD Phase III trial.
Source: BioSpace